MedRx Co., Ltd (4586.T)

JPY 84.0

(-3.45%)

Market Cap (In JPY)

3.97 Billion

Revenue (In JPY)

26 Million

Net Income (In JPY)

-932 Million

Avg. Volume

1.65 Million

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
80.0-199.0
PE
-
EPS
-
Beta Value
1.154
ISIN
JP3921220004
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Yonehiro Matsumura
Employee Count
-
Website
https://www.medrx.co.jp
Ipo Date
2013-02-14
Details
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.